摘要 Tumor-associated macrophages (TAMs) shape tumor immunity and therapeutic efficacy. However, it is poorly understood whether and how post-translational modifications (PTMs) intrinsically affect the phenotype and function of TAMs. Here, we reveal that peptidylarginine deiminase 4 (PAD4) exhibits the...
3.Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs[J]. JAMA Network Open, 2019, 2(5): e192535-e192535. 4.Tr...
1144MHC II neoantigen vaccines improve antitumor immunity and response to immune checkpoint inhibitor in cold tumordoi:10.1136/jitc-2023-SITC2023.1144Background Cold tumor is one of the most refractory solid tumors and experience dismal response to immune checkpoint blockade (ICBs). Most therapeutic ...
Atherosclerosis is accompanied by a CD4 T cell response to apolipoprotein B (APOB). Major histocompatibility complex class II (MHC-II) tetramers can be used to isolate antigen-specific CD4 T cells by flow sorting. Here, we produce, validate and use
Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status pancreatic cancer,immune checkpoint blockade(ICB), PD-1, mAbs, STAT3 inhibitor, humanized Yasufumi Kawasaki, et al. 2019 Alloreactive T Cells Display a Distinct Chemokine Profile...
MHCII类反式激活蛋白调控肿瘤细胞HLA分子的表达
LAG3 is a prominent target since the discovery of PD-1, and presently the only approved LAG3 inhibitor is Relatlimab that is for treating metastatic melanoma [14]. Several other mAbs to LAG3, including LAG525 and REGN3767, are currently undergoing clinical trial [13], [28], [39]. In...
tumor specific MHC-II expression is associated with superior prognosis and/or improved response to immune checkpoint inhibitor therapy in multiple cancers, as well as enhanced tumor rejection in mouse models27,28,59,60,61,62. Recent loss of function and complementation studies in murine carcinoma ce...
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. "Published figure using MHC Class II (I-A/I-E) monoclonal antibody (Product # 16-5321-81) in Flow Cytometry" 3.Frontiers in immunology ...
MHC class II can be loadedwith peptide and transported to the plasma membrane. In addition to this protease inhibitor-protease regulatory mechanisms, DCs have evolved other specializations to make them especially suited for antigen processing and presentation. ...